Crovalimab for treatment of paroxysmal nocturnal haemoglobinuria

Crovalimab is currently in clinical development for patients with paroxysmal nocturnal
haemoglobinuria (PNH). PNH is a rare, acquired, life-threatening disease of the blood. The disease
is characterised by destruction of red blood cells, blood clots, and impaired bone marrow function.
It is a blood condition where blood cells are prone to be attacked by part of the body’s immune
system.